M&A News: GSK Snaps Up Canada’s 35Pharma for $950M, Boosts Pipeline with High BP Drug

FomoAnxiety · 2026-02-25T08:41:18+00:00

GSK is acquiring Canadian biopharmaceutical firm 35Pharma for $950 million to enhance its portfolio with the experimental drug HS235 for pulmonary arterial hypertension. This strategic move follows previous acquisitions to offset patent expirations and boost growth.

FomoAnxiety

2026-02-25 08:41:18

Abstract generation in progress

UK pharma giant GSK Plc GSK -0.24% ▼ announced an agreement to acquire 35Pharma, a Canada-based biopharmaceutical company with an early-stage high blood pressure drug. The company is making this acquisition for $950 million in cash.

Claim 50% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

GSK Enhances Business with 35Pharma and Other Strategic Deals

Through this deal, GSK will acquire 35Pharma’s in-development drug HS235 to treat pulmonary arterial hypertension (PAH), a life-shortening disease marked by high blood pressure in the lungs, and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).

The company expects this drug to offer new development opportunities within its Respiratory, Immunology, and Inflammation portfolio, with the potential to “achieve broader coverage across the metabolic, inflammatory, vascular and fibrotic drivers of multiple chronic diseases that affect the lung, liver and kidney.”

GSK has been bolstering its business with strategic acquisitions to mitigate the impact of the patent expiration of its blockbuster HIV drug, dolutegravir. In January, the company announced the $2.2 billion acquisition of RAPT Therapeutics (RAPT). Earlier this week, GSK announced a $1 billion licensing deal to obtain global rights to develop Frontier Biotechnologies’ two small interfering RNA therapies targeting kidney diseases.

Is GSK Stock a Buy, Sell, or Hold?

Wall Street has a Hold consensus rating on the U.S.-listed shares of GSK based on three Holds, one Buy, and two Sell recommendations. The average GSK stock price target of $47.21 indicates 20.2% downside risk. Shares have risen more than 54% over the past year.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.